Pfizer announced Monday that trials showed its COVID-19 vaccine to be safe and elicited a “robust” antibody response in children ages 5 to 11. These are the first known results of its kind for a COVID-19 vaccine in this age group in the US The data, however, has not yet been peer-reviewed or officially published. However, Pfizer plans to soon submit the documents to the US Food and Drug Administration to request an emergency use authorization for minors.
Pfizer announced Monday that trials showed its COVID-19 vaccine to be safe and elicited a “robust” antibody response in children ages 5 to 11. These are the first known results of its kind for a COVID-19 vaccine in this age group in the US The data, however, has not yet been peer-reviewed or officially published. However, Pfizer plans to soon submit the documents to the US Food and Drug Administration to request an emergency use authorization for minors.